Company Filing History:
Years Active: 2017
Title: Thomas H. Scheuermann: Innovator in HIF Inhibition
Introduction
Thomas H. Scheuermann is an accomplished inventor based in Richardson, TX, whose work focuses on innovative methods for inhibiting the heterodimerization of crucial proteins involved in cellular processes. His research aims to advance our understanding of hypoxia-inducible factors (HIFs) and their role in various diseases.
Latest Patents
Scheuermann holds a patent titled "Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)." This patent describes a method for inhibiting the interaction between HIF-2α and HIF1β by employing small molecules that target the HIF-2α PAS-B domain cavity. Notably, this approach does not affect the heterodimerization of HIF1α to HIF1β, providing a selective mechanism for therapeutic intervention in diseases where HIF-2α activity plays a critical role.
Career Highlights
Thomas H. Scheuermann is actively engaged in his work with the University of Texas System, contributing to groundbreaking research in the field of cancer biology and other hypoxia-related diseases. His innovative approach has garnered attention, leading to advancements in targeted therapies.
Collaborations
Throughout his career, Scheuermann has collaborated with prominent scientists, including Richard Keith Bruick and Charles G. Caldwell. These partnerships have enhanced his research endeavors and facilitated the advancement of his patented technologies.
Conclusion
Thomas H. Scheuermann exemplifies the spirit of innovation, with a focused approach to developing selective inhibitors that have the potential to influence treatment strategies for diseases associated with HIF-2α. His contributions through patenting and collaborative efforts mark him as a significant figure in the realm of biomedical research.